Evidence map›Paper›PMID 38293425›Full record

ArticleHeliyon2024

FH deficient uterine leiomyomas-a case series.

Meenakshi Kamboj, Prerna Chadha, Anila Sharma, Divya Bansal, Gurudutt Gupta, Anurag Mehta

Open access · goldAbstract readCase Reports
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Meenakshi KambojDepartment of Laboratory and Transfusion Services, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India, 110015.
Prerna ChadhaDepartment of Laboratory and Transfusion Services, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India, 110015.
Anila SharmaDepartment of Laboratory and Transfusion Services, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India, 110015.
Divya BansalDepartment of Laboratory and Transfusion Services, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India, 110015.
Gurudutt GuptaDepartment of Laboratory and Transfusion Services, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India, 110015.
Anurag MehtaDepartment of Laboratory and Transfusion Services, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India, 110015.
Rajiv Gandhi Cancer Institute and Research Centre · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Fumarate hydratase (FH) deficient uterine leiomyomas account for only 0.4 % of all uterine leiomyomas. They are characterized by some distinct histological features and may be associated with Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Methods: Herein we present a series of five cases of FH deficient uterine leiomyomas in patients with a mean age of 30 years. All five patients underwent myomectomy. Three of these cases had an outside histopathologic diagnosis ranging from Smooth muscle tumor of uncertain malignant potential (STUMP) to Leiomyosarcoma while two cases were operated at our centre. All five cases were reported as suggestive of FH deficient leiomyomas and were advised germline testing along with genetic counselling. Results: Immunohistochemically four of the cases showed moderate to strong positivity for 2-SC with a complete loss or reduced expression of FH while one case showed absence of 2-SC staining. Discussion: Mutations in FH lead to reduced enzyme activity and accumulation of fumarate leading to a complete loss or aberrant reduced expression seen on immunohistochemistry, which confirms the diagnosis. It is important to differentiate it from a leiomyosarcoma or other malignant spindle cell tumors as these tumors follow a benign course. Their association with HLRCC also needs to be established for a suitable follow up since HLRCC-associated RCCs are often aggressive. Conclusion: Management of such leiomyomas is myomectomy or hysterectomy with advice of genetic testing to rule out HLRCC. Histomorphology and immunohistochemistry are imperative for a correct and timely diagnosis.

Indexed as

Case seriesFumarate hydratase (FH)HLRCCLeiomyoma

Identifiers

PMID38293425
PMCPMC10826412
OpenAlexW4390700748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.